Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-05-22
2011-10-18
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S113000
Reexamination Certificate
active
08039469
ABSTRACT:
Compounds of formula Iwherein:R1isand R2, R4, and R6-9are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
REFERENCES:
patent: 1 020 462 (2000-07-01), None
patent: 1 020 462 (2004-02-01), None
Apr. 8, 2011 Non-Final Office Action issued in connection with U.S. Appl. No. 12/470,525.
Ayral-Kaloustian Semiramis
Chen Zecheng
Curran Kevin Joseph
Dehnhardt Christoph Martin
Delos Santos Efren Guillermo
Anderson Rebecca
Rubin David
Wyeth LLC
LandOfFree
Triazine compounds as PI3 kinase and mTOR inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazine compounds as PI3 kinase and mTOR inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazine compounds as PI3 kinase and mTOR inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301837